Target intelligence / Profile preview

Hemagglutinin (HA) of G4 Eurasian avian-like H1N1 swine influenza A virus (HA)

Target
HA
Molecular classification
Viral surface glycoprotein, Class I fusion protein, Lectin, Receptor
01

Overview

Hemagglutinin (HA) is the primary surface glycoprotein of the G4 Eurasian avian-like (EA) H1N1 swine influenza virus, a genotype that has become predominant in swine populations and poses a significant zoonotic risk to humans (Sun et al., 2020, PNAS). The protein functions as a homotrimer, where each monomer is composed of two subunits, HA1 and HA2, responsible for receptor binding and membrane fusion, respectively (Kadam & Wilson, 2012, Science). Specifically, the G4 EA H1N1 HA has evolved to preferentially bind to alpha-2,6-linked sialic acids, which are prevalent in the human upper respiratory tract, facilitating efficient transmission and replication in human cells (Sun et al., 2020, PNAS). As the major antigen of the virus, HA is the central target for the host immune response and the primary component of seasonal and pre-pandemic vaccines. Therapeutic strategies targeting HA include small-molecule fusion inhibitors like Umifenovir and various monoclonal antibodies designed to neutralize the virus by blocking its attachment or entry into host cells (Blaising et al., 2014, Antiviral Res). Monitoring mutations in the HA head domain is essential for assessing the pandemic risk and maintaining vaccine efficacy against this emerging strain.

Other names
G4 EA H1N1 HemagglutininH1 HemagglutininSurface glycoprotein HAHemagglutinin protein
02

Mechanism of action

Inhibition of viral attachment to host cell sialic acid receptors and prevention of pH-dependent membrane fusion within the endosome (Blaising et al., 2014; Kadam & Wilson, 2012).

03

Biological functions

Viral attachmentReceptor bindingMembrane fusionViral entryEndocytosis
04

Disease associations

Swine influenzaZoonotic infectionRespiratory tract infectionPandemic threat
05

Safety considerations

Antigenic drift leading to vaccine escapePotential for antibody-dependent enhancement (ADE)High mutation rate in the globular head domain (Webster et al., 1992)
06

Interacting drugs

Umifenovir

2 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HI) titerMicroneutralization (MN) titerHA-specific IgG levels

Beyond the preview

Go deeper on Hemagglutinin (HA) of G4 Eurasian avian-like H1N1 swine influenza A virus (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin (HA) of G4 Eurasian avian-like H1N1 swine influenza A virus (HA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call